Halozyme Expands Collaboration With argenx
MT newswire2026/10/06 21:5805:58 PM EDT, 10/06/2026 (MT Newswires) -- Halozyme Therapeutics (HALO) said late Tuesday it has expanded its global collaboration and license agreement with argenx (ARGX) to develop and commercialize Enhanze. The expanded agreement increases argenx's exclusive access to Enhanze to eight targets from six, the company said. Halozyme said it is eligible to receive payments upon achievement of milestones and will receive royalties on net sales of products using Enhanze, a drug delivery technology.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia Stock Faces Critical Warning Sign. Is the AI Trade Breaking?
Deutsche Bank estimates the impact of rising interest rates: US major banks face capital pressure, and stock buybacks may collectively hit the brakes.
Deutsche Bank recently released an industry research report focusing on the capital pressure faced by large US banks amid a significant rise in interest rates expected in Q3 2026.
United States Dollar Index weakens further amid correction in US bond yields
AI data center demand surges, Lumentum (LITE.US) optical component orders booked until 2029
As technology companies race to build high-speed AI data centers, Lumentum's (LITE.US) optical components are nearly "sold out," with orders scheduled through early 2029.
Crypto prices
More
